机构：[1]Institute of Immunology, PLA, Third Military Medical University, 400038 Chongqing, China[2]Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry ofEducation, Zhongshan School of Medicine, Sun Yat-sen University, 510080 Guangzhou, China[3]Guangdong Provincial People’s Hospital, Guangdong Academy of MedicalSciences, 510080 Guangzhou, China[4]State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 150001Harbin, Heilongjiang, China[5]College of Veterinary Medicine, Northeast Agricultural University, 150030 Harbin, Heilongjiang, China[6]Cancer Center, The General Hospital ofWestern Theater Command, 610083 Chengdu, Sichuan, China[7]Biomedical Analysis Center, Third Military Medical University, 400038 Chongqing, China[8]ComparativeImmunology Research Center, College of Veterinary Medicine, China Agricultural University, 100193 Beijing, China[9]Key Laboratory of Animal Epidemiology of the Ministry ofAgriculture, College of Veterinary Medicine, China Agricultural University, 100193 Beijing, China[10]Chongqing Public Health Medical Center, 400038 Chongqing, China[11]Guangzhou Eighth People’s Hospital, Guangzhou Medical University, 510050 Guangzhou, China
COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.
基金：
This work was supported by grants from the National Science and Technology Major Project (No. 2017ZX10202102-006-002 to L.Y.), the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.), and the National Science and Technology Major Project (2016ZX09J16105-001-002 to L.Y.).
第一作者机构：[1]Institute of Immunology, PLA, Third Military Medical University, 400038 Chongqing, China
共同第一作者：
通讯作者：
通讯机构：[2]Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry ofEducation, Zhongshan School of Medicine, Sun Yat-sen University, 510080 Guangzhou, China[11]Guangzhou Eighth People’s Hospital, Guangzhou Medical University, 510050 Guangzhou, China
推荐引用方式(GB/T 7714)：
Xiangyu Chen,Zhiwei Pan,Shuai Yue,et al.Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.[J].SIGNAL TRANSDUCTION AND TARGETED THERAPY.2020,5(1):doi:10.1038/s41392-020-00301-9.
APA：
Xiangyu Chen,Zhiwei Pan,Shuai Yue,Fei Yu,Junsong Zhang...&Lilin Ye.(2020).Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19..SIGNAL TRANSDUCTION AND TARGETED THERAPY,5,(1)
MLA：
Xiangyu Chen,et al."Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.".SIGNAL TRANSDUCTION AND TARGETED THERAPY 5..1(2020)
医学